LGR5-Targeted antibody-drug conjugate eradicates gastrointestinal tumors and prevents recurrence

Molecular Cancer Therapeutics

Volumn 15, Issue 7, 2016, Pages 1580-1590

  Gong, Xing ^a   Azhdarinia, Ali ^a   Ghosh, Sukhen C ^a   Xiong, Wei ^a   An, Zhiqiang ^a   Liu, Qingyun ^a   Carmon, Kendra S ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; G PROTEIN COUPLED RECEPTOR; LEUCINE RICH REPEAT CONTAINING G PROTEIN COUPLED RECEPTOR 5; MONOCLONAL ANTIBODY; MONOMETHYL AURISTATIN E LEUCINE RICH REPEAT CONTAINING G PROTEIN COUPLED RECEPTOR 5 MONOCLONAL ANTIBODY CONJUGATE; PROTEINASE; UNCLASSIFIED DRUG; VEDOTIN; ANTINEOPLASTIC AGENT; LGR5 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER PREVENTION; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TRANSPORT; FEMALE; GASTROINTESTINAL TUMOR; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LYSOSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECURRENT DISEASE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR RECURRENCE; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; FEMALE; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION; HUMANS; IMMUNOCONJUGATES; MICE; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, G-PROTEIN-COUPLED; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84979556369     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0114     Document Type: Article

References (44)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
2. Hirsch D, Barker N, McNeil N, Hu Y, Camps J, McKinnon K, et al. LGR5 positivity defines stem-like cells in colorectal cancer. Carcinogenesis 2014;35:849-58.
3. McClanahan T, Koseoglu S, Smith K, Grein J, Gustafson E, Black S, et al. Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors. Cancer Biol Ther 2006;5:419-26.
4. Xi HQ, Cai AZ, Wu XS, Cui JX, Shen WS, Bian SB, et al. Leucine-rich repeatcontaining G-protein-coupled receptor 5 is associated with invasion, metastasis, and could be a potential therapeutic target in human gastric cancer. Br J Cancer 2014;110:2011-20.
5. Yamamoto Y, Sakamoto M, Fujii G, Tsuiji H, Kenetaka K, Asaka M, et al. Overexpression of orphan G-protein-coupled receptor, Gpr49, in human hepatocellular carcinomas with beta-catenin mutations. Hepatology 2003;37:528-33.
6. Barker N, Huch M, Kujala P, van de Wetering M, Snippert HJ, van Es JH, et al. Lgr5(?ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell 2010;6:25-36.
7. Barker N, Rookmaaker MB, Kujala P, Ng A, Leushacke M, Snippert H, et al. Lgr5(?ve) stem/progenitor cells contribute to nephron formation during kidney development. Cell Rep 2012;2:540-52.
8. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007;449:1003-7.
9. Ng A, Tan S, Singh G, Rizk P, Swathi Y, Tan TZ, et al. Lgr5 marks stem/ progenitor cells in ovary and tubal epithelia. Nat Cell Biol 2014;16: 745-57.
10. Plaks V, Brenot A, Lawson DA, Linnemann JR, Van Kappel EC, Wong KC, et al. Lgr5-expressing cells are sufficient and necessary for postnatal mammary gland organogenesis. Cell Rep 2013;3:70-8.
11. Munoz J, Stange DE, Schepers AG, van de Wetering M, Koo BK, Itzkovitz S, et al. The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent '?4' cell markers. EMBO J 2012;31:3079-91.
12. van der Flier LG, Haegebarth A, Stange DE, van de Wetering M, Clevers H. OLFM4 is a robust marker for stem cells in human intestine and marks a subset of colorectal cancer cells. Gastroenterology 2009;137:15-7.
13. Carmon KS, Gong X, Lin Q, Thomas A, Liu Q. R-spondins function as ligands of the orphan receptors LGR4 and LGR5 to regulate Wnt/betacatenin signaling. Proc Natl Acad Sci U S A 2011;108:11452-7.
14. de Lau W, Barker N, Low TY, Koo BK, Li VS, Teunissen H, et al. Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. Nature 2011;476:293-7.
15. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009;457:608-11.
16. Han Y, Xue X, Jiang M, Guo X, Li P, Liu F, et al. LGR5, a relevant marker of cancer stem cells, indicates a poor prognosis in colorectal cancer patients: a meta-analysis. Clin Res Hepatol Gastroenterol 2015;39:267-73.
17. Hsu HC, Liu YS, Tseng KC, Hsu CL, Liang Y, Yang TS, et al. Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer. Int J Colorectal Dis 2013;28:1535-46.
18. Kemper K, Prasetyanti PR, De Lau W, Rodermond H, Clevers H, Medema JP. Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells. Stem Cells 2012;30:2378-86.
19. Kobayashi S, Yamada-Okabe H, Suzuki M, Natori O, Kato A, Matsubara K, et al. LGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution. Stem Cells 2012;30:2631-44.
20. Saigusa S, Inoue Y, Tanaka K, Toiyama Y, Kawamura M, Okugawa Y, et al. Significant correlation between LKB1 and LGR5 gene expression and the association with poor recurrence-free survival in rectal cancer after preoperative chemoradiotherapy. J Cancer Res Clin Oncol 2013;139:131-8.
21. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
22. Gerger A, Zhang W, Yang D, Bohanes P, Ning Y, Winder T, et al. Common cancer stem cell gene variants predict colon cancer recurrence. Clin Cancer Res 2011;17:6934-43.
23. Lei ZJ, Wang J, Xiao HL, Guo Y, Wang T, Li Q, et al. Lysine-specific demethylase 1 promotes the stemness and chemoresistance of Lgr5? liver cancer initiating cells by suppressing negative regulators of beta-catenin signaling. Oncogene 2015;34:3214.
24. Xi HQ, Cui JX, Shen WS, Wu XS, Bian SB, Li JY, et al. Increased expression of Lgr5 is associated with chemotherapy resistance in human gastric cancer. Oncol Rep 2014;32:181-8.
25. Teicher BA. Antibody-drug conjugate targets. Curr Cancer Drug Targets 2009;9:982-1004.
26. Trail PA. Antibody drug conjugates as cancer therapeutics. Antibodies 2013;2:113-29.
27. Carmon KS, Lin Q, Gong X, Thomas A, Liu Q. LGR5 interacts and Cointernalizes with Wnt receptors to modulate Wnt/beta-catenin signaling. Mol Cell Biol 2012;32:2054-64.
28. Snyder JC, Rochelle LK, Lyerly HK, Caron MG, Barak LS. Constitutive internalization of the leucine-rich G protein-coupled receptor-5 (LGR5) to the trans-Golgi network. J Biol Chem 2013;288: 10286-97.
29. Tian H, Biehs B, Warming S, Leong KG, Rangell L, Klein OD, et al. A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable. Nature 2011;478:255-9.
30. Clevers JC, Barker N, Haegebarth A, Van DWML, inventors. Antibodies recognizing endogenous human lgr5 and/or lgr6. WIPO patent WO 2010016766 A3. 2010 May 6.
31. Montgomery DL, Wang YJ, Hrin R, Luftig M, Su B, Miller MD, et al. Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41. MAbs 2009;1:462-74.
32. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778-84.
33. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004;10:7063-70.
34. Sato T, Stange DE, Ferrante M, Vries RG, Van Es JH, Van den Brink S, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 2011; 141:1762-72.
35. Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 2013;45:1113-20.
36. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
37. Polson AG, Calemine-Fenaux J, Chan P, Chang W, Christensen E, Clark S, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res 2009;69:2358-64.
38. Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep 2015;35:pii:e00225.
39. Sasaki Y, Kosaka H, Usami K, Toki H, Kawai H, Shiraishi N, et al. Establishment of a novel monoclonal antibody against LGR5. Biochem Biophys Res Commun 2010;394:498-502.
40. Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 2006;66:3214-21.
41. Takeda N, Jain R, LeBoeuf MR, Wang Q, Lu MM, Epstein JA. Interconversion between intestinal stem cell populations in distinct niches. Science 2011;334:1420-4.
42. He S, Zhou H, Zhu X, Hu S, Fei M, Wan D, et al. Expression of Lgr5, a marker of intestinal stem cells, in colorectal cancer and its clinicopathological significance. Biomed Pharmacother 2014;68:507-13.
43. Liu YS, Hsu HC, Tseng KC, Chen HC, Chen SJ. Lgr5 promotes cancer stemness and confers chemoresistance through ABCB1 in colorectal cancer. Biomed Pharmacother 2013;67:791-9.
44. Junttila MR, Mao W, Wang X, Wang BE, Pham T, Flygare J, et al. Targeting LGR5? cells with an antibody-drug conjugate for the treatment of colon cancer. Sci Transl Med 2015;7:314ra186.